Fibromyalgia News

Developing myalgic encephalomyelitis/chronic fatigue syndrome is significantly more likely after a case of COVID-19, an important connection for rheumatologists as they sort through symptoms and medical histories for a diagnosis, data show.

Duloxetine, milnacipran and pregabalin can yield significant pain relief over at least 12 weeks for approximately one out of 10 adults with fibromyalgia, according to an analysis of Cochrane reviews published in Rheumatology.

WASHINGTON — Patients who use medication or surgery to achieve at least 5% weight loss demonstrate greater improvements in patient-reported outcomes across various rheumatic diseases, according to data presented at ACR Convergence 2024.

WASHINGTON — Approximately 20% of patients meeting the 2016 fibromyalgia criteria report post-exertional malaise, which itself may be key to understanding both long COVID and fatigue in patients with rheumatic diseases, according to data.

Despite a lack of “gold standard” evidence surrounding cannabis use for musculoskeletal pain, rheumatologists must not turn a blind eye to how such products are used by their patients in the real world, according to researchers.

The FDA has granted fast track designation to a sublingual tablet form of the muscle relaxant cyclobenzaprine hydrochloride for the management of fibromyalgia, according to a press release from the manufacturer.

Rheumatoid arthritis and fibromyalgia are among the most common comorbidities identified in patients following a diagnosis of osteoarthritis, according to data presented at the EULAR 2024 Congress.

Among adults with arthritis, severe joint pain is significantly more prevalent in Black, Hispanic, American Indian and Alaska Native patients vs. white patients, according to data published in Arthritis Care & Research.

A blood sample analysis using Raman spectroscopy, combined with statistical modeling, was sufficient to diagnose fibromyalgia, according to data published in Biomedicines.